贝瑞基因(000710) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was ¥280,207,812.40, a decrease of 10.62% compared to ¥313,494,177.23 in the same period last year[5] - The net loss attributable to shareholders was ¥20,738,437.15, representing a 73.86% increase from a loss of ¥11,928,399.03 in the previous year[5] - The company's basic and diluted earnings per share were both -¥0.06, a decline of 50.00% from -¥0.04 in the same period last year[5] - Net loss for Q1 2023 was CNY 20,110,444.46, compared to a net loss of CNY 12,217,400.42 in Q1 2022, indicating a worsening of 64.5%[18] - The company reported a total comprehensive loss of CNY 22,543,430.36 for Q1 2023, compared to a loss of CNY 13,266,230.07 in Q1 2022[18] Cash Flow - The net cash flow from operating activities improved by 17.68%, amounting to -¥41,528,166.03 compared to -¥50,449,164.21 in the prior year[5] - The company's cash flow from operating activities was CNY 292,298,259.97 in Q1 2023, down from CNY 382,947,930.27 in Q1 2022, representing a decline of 23.6%[20] - The net cash flow from financing activities was -¥7,632,206.64, compared to -¥94,916.69 in Q1 2022, showing a significant deterioration[22] - The total cash outflow from operating activities was 337,608,941.20, compared to 435,891,737.57 in Q1 2022, indicating a reduction of about 22.5%[21] - Total cash inflow from investment activities was 6,484,002.22, while cash outflow was 2,001,375.48, resulting in a net cash flow of 4,482,626.74, compared to -26,194,475.14 in the same period last year[21] Assets and Liabilities - Total assets as of March 31, 2023, were ¥3,170,793,442.57, a decrease of 0.94% from ¥3,200,862,871.74 at the end of the previous year[5] - The total liabilities as of Q1 2023 were CNY 864,689,294.83, slightly down from CNY 871,535,028.84 in the previous quarter[18] - The total equity attributable to shareholders decreased by 1.04% to ¥2,277,535,038.01 from ¥2,301,386,725.87 at the end of the previous year[5] - The company's long-term equity investments decreased to CNY 104,727,156.18 from CNY 112,536,596.20, a decline of approximately 7%[14] Operational Efficiency - Total operating costs for Q1 2023 were CNY 282,899,819.60, down from CNY 309,299,721.50 in the previous year, reflecting a reduction of 8.5%[17] - Research and development expenses decreased to CNY 20,680,673.90 in Q1 2023 from CNY 26,127,459.15 in Q1 2022, a reduction of 21.0%[17] - The company experienced a 35.10% decrease in prepayments, which fell to ¥22,284,411.38 from ¥34,338,731.67[8] Income and Other Financial Metrics - Other income decreased by 37.10%, totaling ¥1,412,798.46 compared to ¥2,246,212.02 in the same period last year[8] - The company reported a significant increase in credit impairment losses, which rose by 157.90% to -¥6,670,255.61 from -¥2,586,347.73 in the previous year[8] - The company received tax refunds amounting to 231,446.97, compared to 23,868.88 in the previous year, marking a substantial increase[21] - The company paid 16,170,026.56 in taxes, down from 22,336,177.06 in Q1 2022, reflecting a decrease of approximately 27.6%[21] Strategic Focus - The report indicates a strategic focus on maintaining liquidity while managing receivables and inventory levels effectively[13] - The company is actively managing its financial assets, with trading financial assets remaining stable at CNY 4,505,243.01[14]